 |
Popular Topics |
|
Ask The Experts |
|
IVDT Insight Blog |
|
Business Strategy |
In September of last year, Sony Corp. acquired venture corporation Micronics Inc. (Redmond, WA) through its wholly owned subsidiary, Sony Corp. of America. Sony bought Micronics to boost its own R&D in the area of point-of-care diagnostic equipment and to accelerate commercialization of these products.
“We don’t have a specific business plan to announce at this time,” says Mack Araki, public affairs, Sony Corp. of America. “Our hope is that the acquisition of...
In April Seegene Inc. (Seoul) announced a partnership with Samsung Medical Center (Seoul) to codevelop molecular diagnostics for cancer. Seegene will bring to this collaboration its molecular diagnostic technology knowledge, and Samsung Medical Center will contribute its clinical and disease-pathology expertise. Samsung Medical Center will also provide the first test sites for the tests. As part of Seegene’s initiatives in personalized medicine, the company will also develop new tests for...
Industry observers and Wall Street traders alike have taken a keen interest in Gen-Probe’s activities and investor announcements this quarter. The interest began in late April, when a news item on Bloomberg’s Web site reported that Gen-Probe had hired financial giant Morgan Stanley to find it a buyer. The Bloomberg story cited “three people with knowledge of the sale,” who were not identified by name, as sources. In response, Gen-Probe’s shares jumped around 13...
In a move consistent with its busy acquisition history in 2010, Thermo Fisher Scientific (TFS) announced at the end of last year its plans to acquire chromatography-system manufacturer Dionex Corp. (Sunnyvale, CA). TFS has also recently completed its sale of Athena Diagnostics and Lancaster Laboratories, two laboratory-testing-services businesses.
Proposed Dionex Purchase. As of April 4 of this year, TFS had extended its cash tender offer to 7:00 p.m. EST on May 13. The proposed acquisition...
Investment banking firm Goldman Sachs (New York) has initiated coverage on the following six IVD companies: Alere, Cepheid, Gen-Probe, Hologic, Myriad Genetics, and Qiagen. In an equity research report, Goldman Sachs analysts discussed various factors that will affect the IVD industry both positively and negatively. According to the analysts, one of the factors that will contribute positively is the transition to molecular testing.
“Advances in knowledge around the genetic underpinnings...
Today a nurse can test a senior citizen for C. difficile in a long-term-care facility. Within hours, the test indicates that special care is required to prevent the spread of this healthcare-associated infection. In the near future, a molecular assay may be able to detect ovarian cancer in a 45-year-old woman with persistent stomach pain, before the cancer spreads to other organs.
Advances in genetic and molecular research are leading to many new and promising technologies like these,...
In a move consistent with its busy acquisition history in 2010, Thermo Fisher announced at the end of last year its plans to acquire chromatography-system manufacturer Dionex Corp. (Sunnyvale, CA). The proposed acquisition comes as the most recent in a string of acquisitions, mostly of companies integrated into Thermo Fisher’s Analytical Technologies segment. Dionex will be brought into the same group; however, unlike the other other three 2010 additions to that division, Dionex...
GE Healthcare purchased Clarient Inc. (Aliso Viejo, CA) late last year. The acquisition was announced in October; U.S. regulators approved the transaction the following month.
GE, a well-known player in diagnostic imaging, is looking to lengthen its reach into molecular diagnostics (MDx), particularly in the oncology realm. With its acquisition of Clarient, it gains the potential for playing a large, comprehensive role in diagnosing and treating cancer. “Clarient is a clear leader...
Two major business deals have taken place recently that are of interest to IVD manufacturers. The first is Roche’s acquisition of BioImagene, and the second is LabCorp’s acquisition of Genzyme Genetics. All of this M&A activity is an overall positive for the IVD industry, says Manfred Scholz, president, Scholz Consulting Partners LLC. The Roche deal in particular is quite important for the industry, he adds.
Roche Acquires BioImagene. Roche (Basel, Switzerland) announced in late...
The process of bringing a new IVD product or system to market involves many crucial milestones. During product development, it is important not only to optimize the IVD’s design, but also to anticipate the many requirements that must be satisfied to allow successful market introduction. Regardless of where it is in the process, and whether it is attempting to commercialize a novel and innovative first IVD device or manages an extensive product line, an IVD manufacturer may consider...
|
Most Recent |
Advertisers | Privacy Policy | Contact | Subscribe | Sitemap
© UBM Canon 1996-2013